IMR Press / CEOG / Volume 46 / Issue 5 / DOI: 10.12891/ceog5179.2019

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Case Report
The increased cellular permeability syndrome manifesting as severe idiopathic type urinary incontinence
Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA
2 Cooper Institute for Reproductive Hormonal Disorders, P.C. Mt. Laurel, NJ, USA
*Correspondence: (J.H. CHECK)
Clin. Exp. Obstet. Gynecol. 2019, 46(5), 812–814;
Published: 10 October 2019

Purpose: To evaluate the efficacy of treatment with dextroamphetamine sulfate for severe idiopathic urgency urinary incontinence refractory to treatment with the selective beta 3 adrenergic agonist, mirabegron. Materials and Methods: Dextroamphetamine sulfate extended release capsule was started at 9.4 mg and increased to 15.7 mg in a woman with two years of severe urgency urinary incontinence. Results: The urgency urinary incontinence completely resolved, as did the fibromyalgia, headaches, and chronic fatigue syndrome. The symptoms have remained eradicated for over one year while treatment continues. Conclusions: Idiopathic urgency urinary incontinence (neurogenic bladder) has been found to be another manifestation of the increased cellular permeability syndrome. Similar to the other chronic disorder associated with the increased cellular permeability syndrome, idiopathic urgency urinary incontinence responds well to dextroamphetamine sulfate treatment despite failure to respond to standard therapy.

Idiopathic urgency urinary incontinence
Neurogenic bladder
Dextroamphetamine sulfate
Increased cellular permeability syndrome
Back to top